A variant of human paraoxonase/arylesterase (HUMPONA) gene is a risk factor for coronary artery disease.

Coronary artery disease (CAD) is a complex trait caused by a number of genetic and environmental factors. Recently, paraoxonase/arylesterase (PONA) enzyme has been implicated in the pathogenesis of atherosclerosis. There is a 10-40-fold variability in the activity of this enzyme among individuals. This variability is due to the presence of an A/G polymorphism in the coding region of the gene (HUMPONA). The A and G alleles code for glutamine (A genotype) and arginine (B genotype), respectively. Individuals with A genotype have a lower enzymatic activity than those with B genotype. We determined the HUMPONA genotypes and alleles in 223 patients with angiographically documented CAD and in 247 individuals in the general population. The distribution of genotypes were in Hardy-Weinberg equilibrium in patients and in controls. Genotypes A and B were present in 120 (49%) and 28 (11%) individuals in controls and in 68 (30%) and 40 (18%) patients with CAD, respectively (chi squared= 16.5, P= 0.0003). The frequency of the A allele was 0.69 in controls and 0.56 in patients (OR= 1.7, P= 0.0001). There were no differences in the distribution of HUMPONA genotypes in the subgroups of patients with restenosis, myocardial infarction, or any of the conventional risk factors for CAD as compared with corresponding subgroups. In summary, variants of the HUMPONA gene are involved in predisposition to coronary atherosclerosis.

[1]  J. Witte,et al.  Genetic dissection of complex traits , 1996, Nature Genetics.

[2]  J. Witte,et al.  Genetic dissection of complex traits. , 1994, Nature genetics.

[3]  T. Yee,et al.  Association of angiotensinogen gene T235 variant with increased risk of coronary heart disease , 1995, The Lancet.

[4]  P. Froguel,et al.  Paraoxonase polymorphism in non-insulin dependent diabetes: A link between lipid oxidation and coronary heart disease , 1995 .

[5]  A. Marian,et al.  Apolipoprotein ε4 is not a genetic risk factor for coronary artery disease or restenosis after percutaneous transluminal coronary angioplasty , 1995 .

[6]  P. Froguel,et al.  The relationship between paraoxonase polymorphism and plasma lipids/lipoproteins in non-insulin dependent diabetes , 1995 .

[7]  A. Marian,et al.  Angiotensin-I converting enzyme genotype DD is a risk factor for coronary artery disease. , 1995, Journal of investigative medicine : the official publication of the American Federation for Clinical Research.

[8]  A. Hamsten,et al.  Allele-specific increase in basal transcription of the plasminogen-activator inhibitor 1 gene is associated with myocardial infarction. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[9]  T. Iwamoto,et al.  Molecular variant of angiotensinogen gene is associated with coronary atherosclerosis. , 1995, Circulation.

[10]  石上友章.  Molecular Variant of Angiotensiongen Gene Is Associated With Coronary Atherosclerosis(冠状動脈硬化症とのアンジオテンシンノーゲン遺伝子多型との関連研究) , 1995 .

[11]  L. Berkman,et al.  Genetic susceptibility to death from coronary heart disease in a study of twins. , 1994, The New England journal of medicine.

[12]  R. Ward,et al.  Apolipoprotein Polymorphisms Fail to Define Risk of Coronary Artery Disease: Results of a Prospective, Angiographically Controlled Study , 1994, Circulation.

[13]  S. Kanemitsu,et al.  Effects of LDL apheresis on restenosis after angioplasty. , 1994, Chemistry and physics of lipids.

[14]  D. Adler,et al.  Human and rabbit paraoxonases: purification, cloning, sequencing, mapping and role of polymorphism in organophosphate detoxification. , 1993, Chemico-biological interactions.

[15]  C. Abbott,et al.  Is paraoxonase related to atherosclerosis. , 1993, Chemico-biological interactions.

[16]  S. Adkins,et al.  Molecular basis for the polymorphic forms of human serum paraoxonase/arylesterase: glutamine or arginine at position 191, for the respective A or B allozymes. , 1993, American journal of human genetics.

[17]  D. Adler,et al.  The molecular basis of the human serum paraoxonase activity polymorphism , 1993, Nature Genetics.

[18]  Philippe Amouyel,et al.  Deletion polymorphism in the gene for angiotensin-converting enzyme is a potent risk factor for myocardial infarction , 1992, Nature.

[19]  P. Durrington,et al.  Paraoxonase prevents accumulation of lipoperoxides in low‐density lipoprotein , 1991, FEBS letters.

[20]  A. Motulsky,et al.  Role of genetic polymorphism of human plasma paraoxonase/arylesterase in hydrolysis of the insecticide metabolites chlorpyrifos oxon and paraoxon. , 1988, American journal of human genetics.

[21]  Shirley A. Miller,et al.  A simple salting out procedure for extracting DNA from human nucleated cells. , 1988, Nucleic acids research.

[22]  C. Walker,et al.  Distribution of paraoxon hydrolytic activity in the serum of patients after myocardial infarction. , 1986, Clinical chemistry.

[23]  B. La Du,et al.  The human serum paraoxonase/arylesterase polymorphism. , 1983, American journal of human genetics.

[24]  D. Evans,et al.  Genetic polymorphism and interethnic variability of plasma paroxonase activity. , 1976, Journal of medical genetics.